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Available online 17 December 2015Background: Infectious diseases account for a signiﬁcant global burden of disease and substantial investment in
research and development. This paper presents a systematic assessment of research investments awarded to
UK institutions and global health metrics assessing disease burden.
Methods:We systematically sourced research funding data awarded from public and philanthropic organisations
between 1997 and 2013. We screened awards for relevance to infection and categorised data by type of science,
disease area and speciﬁc pathogen. Investments were compared with mortality, disability-adjusted life years
(DALYs) and years lived with disability (YLD) across three time points.
Findings: Between 1997–2013, there were 7398 awards with a total investment of £3.7 billion. An increase in re-
search funding across 2011–2013 was observed for most disease areas, with notable exceptions being sexually
transmitted infections and sepsis research where funding decreased. Most funding remains for pre-clinical re-
search (£2.2 billion, 59.4%). Relative to global mortality, DALYs and YLDs, acute hepatitis C, leishmaniasis and
African trypanosomiasis received comparatively high levels of funding. Pneumonia, shigellosis, pertussis, cholera
and syphilis were poorly funded across all health metrics. Tuberculosis (TB) consistently attracts relatively less
funding than HIV and malaria.
Interpretation:Most infections have received increases in research investment, alongside decreases in global bur-
den of disease in 2013. The UK demonstrates research strengths in some neglected tropical diseases such as
African trypanosomiasis and leishmaniasis, but syphilis, cholera, shigellosis and pneumonia remain poorly
funded relative to their global burden. Acute hepatitis C appears well funded but the ﬁgures do not adequately
take into account projected future chronic burdens for this condition. These ﬁndings can help to inform global
policymakers on resource allocation for research investment.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Funding1. Introduction
Despitemajor advances in vaccines, diagnostics, therapeutics and in-
fection control measures, the “unﬁnished agenda” of infectious diseases
remains a global threat. The Global Burden of Disease (GBD) Study 2013
reports that lower respiratory tract infections, diarrhoeal disease, HIV,
and malaria were four of the top ten causes of disease burden globally,
as measured by disability-adjusted life years (DALYs) (Murray et al.,
2015). These four disease areas, plus tuberculosis (TB), comprised ﬁve
of the top eleven causes of death worldwide in 2013 (GBD 2013don, Farr Institute for Health
Kingdom.
. This is an open access article underMortality and Causes of Death Collaborators, 2014). Infectious diseases
generate a large economic burden (Fonkwo, 2008) with antimicrobial
resistance (AMR), the subject of a World Health Organization (WHO)
action plan (World Health Organization, 2014) and a priority for the
United Kingdom (UK) (Anon.,), European Commission (2011), and the
US Centers for Disease Control and Prevention (CDC) (Anon.,), projected
to cost an estimated $100 trillion by the year 2050 if unadressed (Anon.,
2014).
Research is essential to improve the evidence base for policy and
clinical practice. TheUK research funding landscape has several national
and international awarding bodies that invest in pre-clinical (laborato-
ry) science, observational studies, clinical trials, and translational re-
search, with signiﬁcant commitments to infectious disease research.
Earlier research by the Research Investments in Global Health studythe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Total funding, number of studies and mean and median award size of research investment by infection 1997–2013. SD, standard deviation. IQR, inter-quartile range.
Investment 1997–2013 Investment 2011–2013
Disease Number of
awards
Total investment
(£)
Percentage of
total
Mean award, (SD) Median award, (IQR) Number of awards
2011–2013
Percentage of
total
Total funding
(£)
Percentage of 2011–2013
total
Overall 7398 3,725,073,507 n/a 503,524 (1,412,776) 192,143 (63,189–418,015) 1232 n/a 916,960,747 n/a
Disease areas and products
Antimicrobial resistance 413 164,419,467 4.4% 398,110 (901,417) 155,794 (44,065–347,091) 76 6.17% 53,195,899 5.80%
Global health 1712 1,348,277,988 36.2% 787,545 (2,468,415) 253,262 (77,735–589,359) 306 24.84% 343,532,187 37.46%
Gastroenterology 903 355,186,553 9.5% 393,340 (687,605) 218,799 (82,364–394,549) 114 9.25% 90,313,344 9.85%
Healthcare-associated infections 348 105,957,588 2.8% 304,475 (750,448) 71,490 (10,656–252,931) 51 4.14% 43,165,873 4.71%
Hepatology 366 125,058,113 3.4% 341,688 (794,679) 128,340 (43,420–290,954) 44 3.57% 46,794,839 5.10%
HIV 919 651,351,095 17.5% 708,760 (2,350,940) 181,628 (41,468–481,721) 155 12.58% 135,569,246 14.78%
Neglected tropical diseases 490 323,791,367 8.7% 660,798 (2,191,508) 276,730 (107,065–527,303) 83 6.74% 75,444,667 8.23%
Neurology 399 151,371,666 4.1% 379,377 (939,438) 169,212 (70,749–390,007) 60 4.87% 4,226,646 0.46%
Respiratory 1230 556,045,105 14.9% 452,069 (838,744) 207,736 (67,471–445,418) 219 17.78% 145,182,110 15.83%
Sepsis 86 24,762,825 0.7% 287,939 (577,197) 151,855 (54,291–272,451) 7 0.57% 2,210,944 0.24%
Sexually transmitted infections 402 166,144,022 4.5% 413,293 (1,035,635) 112,263 (19,251–269,686) 24 1.95% 17,014,003 1.86%
Diagnostics 484 202,271,238 5.4% 417,915 (1,055,385) 106,001 (19,758–296,732) 77 6.25% 93,692,388 10.22%
Therapeutics 788 662,160,655 17.8% 840,305 (2,683,243) 231,142 (62,947–639,642) 262 21.27% 217,159,123 23.68%
Vaccinology 490 374,959,878 10.1% 765,224 (1,556,168) 266,315 (104,809–730,657) 122 9.90% 119,905,881 13.08%
Speciﬁc infection or disease
African Trypanosomiasis 170 98,621,900 2.6% 580,128 (1,070,225) 288,393 (156,960–505,168) 35 2.84% 29,561,488 3.22%
Aspergillus 32 9,381,561 0.3% 293,173 (680,033) 68,304 (23,920–231,642) 6 0.49% 4,254,846 3.14%
Campylobacter 113 35,796,296 1.0% 316,781 (497,139) 240,419 (95,468–346,045) 26 2.11% 9,775,861 1.07%
Candida 87 31,410,745 0.8% 361,043 (461,554) 282,390 (92,281–416,521) 11 0.89% 6,676,377 0.73%
Chagas disease 18 5,284,555 0.1% 293,586 (222,290) 233,625 (175,747–372,486) 0 0.00% 0 0.00%
Chlamydia 119 25,899,326 0.7% 217,641 (593,623) 60,833 (12,590–196,419) 7 0.57% 2,783,510 0.30%
Cholera 7 1,154,507 0.0% 164,929 (123,277) 89,667 (51,193–287,951) 0 0.00% 0 0.00%
Clostridium 97 56,061,419 1.5% 577,952 (1,089,221) 226,732 (49,926–475,684) 19 1.54% 17,009,293 1.85%
Cytomegalovirus 79 35,695,572 1.0% 451,842 (673,587) 220,703 (118,302–531,000) 11 0.89% 5,287,629 0.58%
Dengue 38 54,430,748 1.5% 1,432,388 (5,674,662) 309,695 (124,361–693,323) 9 0.73% 6,236,268 0.68%
Diphtheria 2 149,094 0.0% n/a n/a 0 0.00% 0 0.00%
(continued on next page)
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Table 1 (continued)
Investment 1997–2013 Investment 2011–2013
Disease Number of
awards
Total investment
(£)
Percentage of
total
Mean award, (SD) Median award, (IQR) Number of awards
2011–2013
Percentage of
total
Total funding
(£)
Percentage of 2011–2013
total
Ebola 0.0% 0 0.00% 0 0.00%
Escherichia coli 130 38,984,636 1.0% 299,881 (290,578) 234,560 (119,663–380,995) 23 1.87% 10,782,819 1.18%
Epstein-Barr Virus 155 51,901,868 1.4% 334,850 (479,035) 164,142 (52,255–389,593) 9 0.73% 4,333,912 0.47%
Gonorrhoea 20 1,448,016 0.0% 72,400 (99,604) 14,485 (3963–146,098) 2 0.16% 440,305 0.05%
Helicobacter 104 18,233,832 0.5% 175,325 (280,233) 95,172 (12,217–203,294) 3 0.24% 2,282,283 0.25%
Helminths 158 80,232,248 2.2% 507,799 (1,221,547) 251,698 (93,055–459,074) 8 0.65% 6,852,922 0.75%
Hepatitis B 82 26,834,637 0.7% 327,251 (708,712) 87,810 (24,062–238,425) 13 1.06% 10,996,796 1.20%
Hepatitis C 272 110,257,438 3.0% 405,358 (926,977) 141,135 (50,250–301,331) 36 2.92% 43,153,957 4.71%
HIV 919 651,351,095 17.5% 708,760 (2,350,940) 181,628 (41,468–481,721) 155 12.58% 135,569,246 14.78%
Human papillomavirus 164 62,219,508 1.7% 379,387 (872,744) 119,037 (39,642–260,832) 17 1.38% 5,994,339 0.65%
Herpes simplex virus 55 26,750,879 0.7% 486,379 (733,513) 225,701 (60,655–458,073) 7 0.57% 3,163,889 0.35%
Inﬂuenza 194 126,643,152 3.4% 652,799 (1,124,119) 308,455 (164,025–736,503) 53 4.30% 39,139,703 4.27%
Leishmaniasis 89 52,894,292 1.4% 594,317 (868,448) 309,522 (121,761–582,645) 11 0.89% 7,257,334 0.79%
Leprosy 2 633,855 0.0% n/a n/a 0 0.00% 0 0.00%
Listeria 13 6,566,639 0.2% 505,126 (452,060) 263,445 (139,604–730,472) 0 0.00% 0 0.00%
Lymphatic ﬁlariasis 10 57,693,197 1.5% 5,769,320 (11,200,387) 806,101 (208,913–3,247,287) 3 0.24% 5,986,094 0.65%
Malaria 621 518,734,860 13.9% 835,321 (2,413,049) 256,064 (75,813–641,805) 117 9.50% 137,212,998 14.96%
Measles 13 6,556,866 0.2% 504,374 (463,858) 331,040 (77,576–777,779) 1 0.08% 1,113,633 0.12%
Meningitis 264 90,609,407 2.4% 343,217 (1,060,577) 155,610 (73,893–266,103) 42 3.41% 32,968,225 3.60%
Norovirus 23 13,181,682 0.4% 573,116 (937,560) 218,767 (61,583–533,797) 11 0.89% 7,580,760 0.83%
Onchocerciasis 8 7,755,554 0.2% 969,444 (1,315,292) 217,587 (30,798–2,005,428) 3 0.24% 5,986,094 0.65%
Pertussis 13 4,108,262 0.1% 316,020 (250,671) 341,788 (46,284–539,766) 4 0.32% 1,527,779 0.17%
Pneumonia 137 59,051,642 1.6% 431,033 (820,052) 206,399 (61,652–401,771) 35 2.84% 28,849,125 3.15%
Polio 13 6,786,968 0.2% 522,074 (596,514) 419,773 (67,163–580,209) 9 0.73% 5,978,072 0.65%
Pseudomonas 59 11,577,984 0.3% 196,237 (239,174) 153,990 (29,367–263,384) 16 1.30% 4,553,921 0.50%
Rotavirus 22 7,752,326 0.2% 352,378 (423,329) 179,221 (148,949–352,758) 3 0.24% 1,097,942 0.12%
Respiratory syncytial virus 56 20,984,547 0.6% 374,724 (482,391) 197,172 (51,855–527,461) 11 0.89% 2,756,796 0.30%
Salmonella 168 81,422,224 2.2% 484,656 (595,724) 291,574 (172,554–518,393) 23 1.87% 21,291,316 2.32%
Schistosomiasis 50 45,767,421 1.2% 915,348 (3,963,046) 215,294 (65,146–469,526) 3 0.24% 2,069,845 0.23%
Shigellosis 12 7,390,226 0.2% 615,852 (534,875) 527,553 (148,386–923,817) 3 0.24% 3,815,542 0.42%
Syphilis 5 1,112,066 0.0% 222,413 (152,855) 221,474 (117,055–253,533) 0 n/a 0 n/a
Tetanus 5 5,727,398 0.1% 1,145,480 (2,083,733) 244,849 (201,515–401,104) 0 n/a 0 n/a
Trachoma 6 7,883,360 0.2% 1,313,893 (1,171,657) 977,242 (342,867–1,928,703) 4 0.32% 3,877,578 0.42%
Tuberculosis 413 239,232,401 6.4% 579,255 (1,097,612) 226,748 (96,244–542,191) 83 6.74% 71,110,945 7.76%
Varicella zoster virus 21 4,721,860 0.0% 224,850 (281,832) 152,770 (50,883–243,513) 1 0.08% 177,901 0.02%
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183M.G. Head et al. / EBioMedicine 3 (2016) 180–190(ResIn, www.researchinvestments.org) has systematically analysed
public and philanthropic awards totalling £2.6 billion to UK institutions
for infectious disease from 1997 to 2010, for funding awarded by infec-
tious disease, microbiology and type of science (Head et al., 2013), in-
cluding for respiratory infectious disease research (Head et al., 2014a)
and pneumonia (Head et al., 2015a), sepsis (Fitchett et al., 2014a),
AMR (Head et al., 2014b), and sexually-transmitted infections (Head
et al., 2015b). Tracking research and development (R&D) investments
provides information and evidence to inform policy on funding deci-
sions. We present an update to the systematic analysis of infectious dis-
ease research awarded by public and philanthropic funders to UK
institutions from 2011 to 2013, and assess funding from 1997–2013
against global measures of mortality, DALYs and years lived with dis-
ability (YLD) across three time points.
2. Methods
Ourmethods for the 1997–2010 analysis are described in detail else-
where (Head et al., 2014a,b,c,d,e,f; Head et al., 2015a,b,c; Fitchett et al.,
2013, 2014b) and adapted in subsequent peer-reviewed publications
(www.researchinvestments.org/publications).
The methods for the updated analysis are broadly similar, in that we
systematically examined award data from 585 public and philanthropic
funding bodies by either searching the databases and information on
their publically available websites, requesting data directly or searching
other funding databases. From the information gathered, we manually
screened each study individually for relevance to infectious disease re-
search.We excluded studies not immediately relevant to infectious dis-
ease, symposium grants, studies related to purely veterinary or plant
infectious disease (but included animal health research incorporating
a clear zoonotic component), research where a viral vector was used
in relation to non-communicable disease, and awards that were led by
a non-UK institution, but had UK collaborators. Of the studies included
in theﬁnal dataset, all had a title or brief descriptor and 65.1% had either
an abstract attached or further information sourced from the internet
(e.g. institutional webpages, clinical trials databases). Private sector
data were not available to analyse in the same detail and therefore
excluded.
Where awards were received from an international funder, curren-
cies were converted to UK pounds using the mean exchange rate in
the year of the award. All grant funding amounts were adjusted for in-
ﬂation and reported in 2013 UK pounds. Awards from 1997–2010 had
been previously adjusted for inﬂation to 2010 levels, but have here
also been adjusted and reported in 2013 UK pounds to allow for up-
dated comparison between years. Ongoing data management and revi-
sion to the overall dataset has resulted in 5 less studies (0.001% change)
than previously reported. Unfunded studies were excluded.
Each study in the dataset was reviewed by MGH and assigned to as
many disease categories as appropriate. Authors VN and NK provided
support for this categorisation process. Studies were also allocated to
one of ﬁve categories along the R&D pipeline: pre-clinical; phase I, II,
or III; product development; public health; and cross-disciplinary re-
search. The introduction of the cross-disciplinary category was a reﬁne-
ment of the previous methodology prompted by an increasing number
of these types of awards (deﬁned as an award containing signiﬁcant
components of a study that covers two areas along the R&D pipeline).
We did not retrospectively apply this new category to the 1997–2010
dataset owing to resource constraints. The public health research cate-
gorywas previously entitled ‘implementation and operational research’.
The change in name better reﬂects the content of this category, and has
not involved any change in which studies are categorised here.
Provisional datasets were circulated to all authors for review and
comment. Further checks involved authors JRF, VN and NK cross-
checking 20% sections of randomly-selected rows of data with any dis-
agreements settled by consensus, and also providing an opinion on
any studies where initial categorisation proved difﬁcult. Authors MGHand JRF further considered difﬁculties in categorisation between phase
I–III studies, and the product development category that includes
phase IV research. Final datasets were then again circulated for further
review by all authors. Two ﬁxed marginal κ scores were calculated
and showed 0.95 for level of agreement on the ‘type of science’
categorisation, and 0.91 for application of the disease categories,
highlighting high levels of independent agreement in the categorisation
process.
As per the earlier analysis (Head et al., 2013), the category of antimi-
crobial resistance includes antibacterial, antiviral, and antifungal resis-
tance. Reference to diagnostics includes screening programmes.
Reference to sexually transmitted infections excludes HIV which is de-
ﬁned in its own category, and neglected tropical diseases were
categorised based on the infections focused on by WHO (http://www.
who.int/neglected_diseases/diseases/en/). Awards were deﬁned as
global health if they i) were considered to pursue a clear non-UK focus
(e.g. ‘tuberculosis in Kenya’), or ii) focused on diseases not endemic in
the UK (e.g. malaria).
Available on the ResIn website (http://researchinvestments.org/
about-the-study/study-methodology/) is the list of included funders
(and excluded funders with reason for exclusions), list of keywords
used to search funder's website, and examples of (and comment on)
the deﬁnitions and categorisations. Stata (V13) software was used for
data analysis.
Global mortality and DALY data were available at time points 2004,
2010 and 2013. Time points for global YLDs were 2005, 2010 and
2013. All burden data were sourced from the ﬁndings of the Global Bur-
den of Disease study, for 2013 (Murray et al., 2015; GBD 2013Mortality
and Causes of Death Collaborators, 2014; Anon., 2015) and for 2010
(Anon., 2015; Murray et al., 2012; Lozano et al., 2012). Burden data
from 2004/05 were obtained directly from colleagues at the Institute
for Health Metrics and Evaluation, Washington. As deﬁned by the GBD
study, YLDs per person from a sequela are equal to the prevalence of
the sequelamultiplied by the disability weight for the health state asso-
ciated with that sequela. YLDs for a disease or injury are the sum of the
YLDs for each sequela associated with the disease or injury (Vos et al.,
2012). DALYS are the product of adding YLLs and YLDs for each age–
sex–country group (Murray et al., 2015).
In order to allowdirect comparison of relative investmentwith glob-
al health metrics across disease areas and between different time pe-
riods, metrics were developed to show ‘investment per mortality/
DALY/YLD observed’, and these were created using the following equa-
tion — (cumulative research investment up to the year before the time
point / number of deaths, DALYs or YLD at time point) / number of
years of investment included.
For example, for assessment of HIV mortality at the 2004 time
point, we took the sum of HIV research investment 1997–2003
(£238,900,938) and divided that by number of deaths reported in
2004 (2,040,000), and divided the result by 7 (the number of years of in-
vestment included) to get an ‘investment per mortality observed’ met-
ric of £16.73.
The use of cumulative investment and the division by number of
years included aimed to reduce the impact of the volatility of annual re-
search funding and short periods between time points.
Ranking scores of the investment metrics were developed for each
infection and across each time point. Infections were ranked in order
of relative investment against burden from high to low and assigned a
score (from 1 to 25). The mean ranking scores across time points and
across mortality, DALY and YLD were used to illustrate relative levels
of investment.
In 2004 mortality, 2005 YLD and all 2013 datasets, only aggregated
data was available for diarrhoea and enteric infectious disease and
lower respiratory tract infections. For Salmonella, Escherichia coli, Shigel-
losis, Vibrio cholerae, Campylobacter, inﬂuenza and pneumonia, propor-
tional estimates were compiled using disaggregated data from the
2010 dataset.
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The analysis for 1997–2013 analysis included funding of £3.7 billion
across 7398 awards (Table 1). Mean funding for all infectious diseases
was £219.1 million per year (435 awards annually). Mean funding per
award was £503,524 (SD £1,412,776) with median funding per award
of £192,143 (IQR £63,189–418,015).Fig. 1. a) Aggregate and b) proportionate funding from 1997–2013 by type of science along t
2013)).Across 2011–2013, there were additional 1232 awards with total
new funding of £917.0 million. Mean annual funding was greater in
2011–2013, amounting to £305.7 million across 411 awards each year.
Mean funding per award was £744,286 (SD £1,360,777), with median
funding per award at £315,918 (IQR £156,283–779,794).
Table 1 shows comparisons of funding for speciﬁc infection and dis-
ease area in 1997–2013 and speciﬁcally the addition of 2011–2013 data.he research and development pipeline (1997–10 data published previously (Head et al.,
Table 2
Years lived with disability (YLD) and ‘investment by YLD observed’ at three time points.
Disease
YLD Investment per YLD observed
2005 2010 2013 2005 2010 2013
Campylobacter 746,000 746,000 637,440 £2.10 £2.51 £3.51
Chagas disease 308,932 303,000 97,500 £1.61 £1.24 £3.39
Chlamydia 632,136 669,000 646,500 £3.64 £2.53 £2.50
Cholera 80,000 80,000 95,958 £0.21 £1.11 £0.75
Dengue 9938 12,000 565,900 £59.79 £308.03 £6.01
Diphtheria 130 110 100 £143.36 £104.26 £93.18
E. coli 1,910,000 1,910,000 1,624,445 £1.08 £1.08 £1.50
Gonorrhoea 233,757 249,000 225,400 £0.43 £0.26 £0.40
Hepatitis A 182,394 185,000 198,000 £0.64 £0.39 £0.29
Hepatitis B 233,179 248,000 172,600 £5.58 £3.90 £9.72
Hepatitis C 36,450 39,000 16,900 £136.61 £119.70 £407.76
Hepatitis E 66,215 69,000 56,600 £0.00 £0.00 £0.00
HIV/AIDS 4,707,104 4,342,000 4,063,700 £7.07 £8.57 £10.02
Inﬂuenza 552,922 583,000 115,225 £6.98 £10.93 £68.69
Leishmaniasis 128,339 124,000 49,700 £16.71 £25.52 £66.52
Malaria 3,887,171 4,070,000 3,170,500 £5.63 £6.95 £10.23
Measles 59,444 31,000 17,300 £7.06 £13.51 £43.35
Meningitis 2,528,495 2,628,000 1,679,100 £1.84 £1.55 £5.35
Pertussis 149,225 122,000 125,500 £1.42 £1.63 £3.33
Pneumonia 572,838 604,000 119,373 £2.56 £3.68 £46.03
Salmonella 513,000 513,000 438,668 £7.96 £8.66 £19.83
Schistosomiasis 2,639,036 2,986,000 2,861,700 £1.77 £1.12 £1.95
Shigellosis 744,000 744,000 596,315 £0.34 £0.37 £1.15
Syphilis 89,379 91,000 584,000 £1.11 £0.94 £0.24
Tetanus 30,245 21,000 13,200 £3.56 £20.98 £54.24
Trypanosomiasis 10,742 80,000 54,000 £386.71 £63.41 £190.48
Tuberculosis 6,797,443 6,774,000 3,669,700 £1.37 £1.83 £6.81
Varicella 185,361 202,000 197,200 £1.37 £1.73 £1.50
Overall 28,033,875 28,425,110 22,092,524 £28.37 £54.02 £87.58
Fig. 2. Investment by years livedwith disability (YLD) observed for selected infections and
across three time points.
185M.G. Head et al. / EBioMedicine 3 (2016) 180–190Total and proportional funding for antimicrobial resistance (5.8% of all
infection research), healthcare-associated infections (4.71%), and viral
hepatology (5.1%) increased in 2011–13 compared with 1997–2010.
Relative funding for sepsis (0.24% of all infection research), sexually-
transmitted (1.86%) and neurological infections (0.46%) declined in
2011–2013 compared with 1997–2010. An observed 36.2% of the total
investment was directly related to global health. There was no public
or philanthropic research investment for Ebola or other haemorrhagic
fevers in 2011–2013. There were large increases in funding for new
products, speciﬁcally diagnostics, therapeutics and vaccines.
There is volatility in annual research funding though an overall in-
crease between 1997 and 2013 (Fig. 1a). TheWellcome Trust is the larg-
est investor in research, having funded 2285 studies (30.9%) totalling
£935.0 million (25.1%), followed by the Medical Research Council
(£924.9 million, 24.8%). The European Commission funded 12.9% of
total investment across 1997–2013, and this increased to 21.6% speciﬁ-
cally across 2011–2013, ahead of the Wellcome Trust (20.9%) and
slightly behind the MRC (21.9%) (Supplementary 1). Alongside these
three funders, the National Institute for Health Research (NIHR, main
funding stream of the UKDepartment of Health), Biotechnology and Bi-
ological Sciences Research Council (BBSRC) and the Bill &Melinda Gates
Foundation combined contributed 84.1% of the overall investment. The
remainder was provided by institutions such as the US National Insti-
tutes for Health (NIH), UK government departments, UK research coun-
cils, other research charities and professional bodies and societies.
The proportion of funding awarded by the type of science (supple-
mentary 2, Fig. 1b) show a gradual increase in investment for public
health research with slight decline for pre-clinical science. Pre-clinical
science overall receives the greatest investment of £2.2 billion (59.4%),
followed by public health research (£954.6 million; 25.9%), with rela-
tively little public or philanthropic investment for phase I–III trials
(£207.3 million; 5.6%) or product development studies (£234.7 million,
6.3%). Cross-disciplinary research accounted for a small number of
awards (0.7% overall, 4.0% in 2011–2013), but a greater proportion ofthe funding (£105.4 million; 2.8% overall, 11.5% in 2011–2013) and
these studies were often consortia-led or programme grants.
Across three time points (2005, 2010, 2013), YLDs for infectious dis-
eases broadly declined (Table 2, Fig. 2). The median ‘investment by YLD
observed’metricwas highest in 2013 (£6.01 comparedwith £3.56 over-
all). Acute hepatitis C and trypanosomiasis consistently received the
greatest relative investment respectively (Table 2). Investment by YLD
observed for inﬂuenza greatly increased in 2013 (£68.69, compared
with £10.93 in 2010, after the 2009 pandemic). Infections such as shig-
ellosis, cholera, syphilis and gonorrhoea were typically amongst those
receiving the lowest relative investment (less than £1.00 per YLD
observed).
The relative level of investment per death, DALY or YLD for all infec-
tions combined consistently increased over time (Tables 2–4). When
Table 3
Mortality and investment by mortality observed at three time points.
Number of deaths Investment per mortality observed
2004 2010 2013 2004 2010 2013
Campylobacter 163,092 109,000 14,100 £10.50 £17.20 £158.67
Chagas disease 11,000 10,300 10,600 £48.61 £36.44 £31.16
Chlamydia 9000 1200 1100 £280.96 £1412.06 £1471.55
Cholera 86,932 58,100 69,900 £0.22 £1.53 £1.03
Clostridium difﬁcile 41,500 £84.43
Dengue 18,000 14,700 9100 £23.01 £251.46 £373.84
Diphtheria 5000 2900 3300 £3.61 £3.95 £2.82
E. coli 313,465 209,500 61,000 £7.31 £9.84 £39.94
Gonorrhoea 1000 900 2300 £78.48 £72.03 £39.35
Hepatitis A 102,800 14,900 £0.00 £0.00
Hepatitis B 105,000 132,200 68,600 £12.99 £7.32 £24.45
Hepatitis C 54,000 16,000 3500 £98.51 £291.77 £1968.88
Hepatitis E 56,600 49,700 £0.00 £0.00
HIV/AIDS 2,040,000 1,465,400 1,341,000 £16.73 £25.39 £30.36
Inﬂuenza 117,632 507,900 105,400 £35.03 £12.55 £75.10
Leishmaniasis 47,000 51,600 62,500 £46.21 £61.33 £52.89
Malaria 889,000 1,169,500 854,600 £25.94 £24.19 £37.94
Measles 424,000 125,400 95,600 £0.65 £3.34 £7.85
Meningitis 340,000 422,900 303,500 £14.87 £9.65 £29.58
Norovirus 1800 £457.70
Pertussis 254,000 81,400 60,600 £0.96 £2.44 £6.90
Pneumonia 1,235,381 1,460,700 784,600 £1.33 £1.52 £7.00
Salmonella 406,233 271,500 239,300 £10.04 £16.37 £36.35
Schistosomiasis 47,000 11,700 5500 £109.01 £284.76 £1012.27
Shigellosis 182,543 122,000 73,900 £1.58 £2.25 £9.27
Syphilis 99,000 113,300 136,800 £1.15 £0.76 £1.02
Tetanus 163,000 61,300 58,900 £0.76 £7.19 £12.15
Trypanosomiasis 52,000 9100 6900 £78.36 £557.48 £1490.69
Tuberculosis 1,464,000 1,196,000 1,290,300 £6.78 £10.35 £19.38
Varicella 6800 7000
Overall 8,527,278 7,790,700 5,734,500 £85.28 £197.11 £337.39
Table 4
Disability-adjusted life years (DALYs) and ‘investment by DALY observed’ at three time points.
DALYs Cumulative investment per DALY observed
2004 2010 2013 2004 2010 2013
Campylobacter 6,131,039 7,541,000 6,132,681 £0.28 £0.25 £0.36
Chagas disease 429,872 546,000 338,000 £1.24 £0.69 £0.98
Chlamydia 3,748,198 714,000 692,000 £0.67 £2.37 £2.34
Cholera 3,628,541 4,463,000 3,629,512 £0.01 £0.02 £0.02
Clostridium difﬁcile
Dengue 669,647 825,000 1,142,000 £0.62 £4.48 £2.98
Diphtheria 173,575 236,000 253,000 £0.10 £0.05 £0.04
E. coli 11,736,863 14,436,000 11,740,005 £0.20 £0.14 £0.21
Gonorrhoea 3,549,975 282,000 313,000 £0.02 £0.23 £0.29
Hepatitis A 1,214,000 £0.05
Hepatitis B 2,067,533 4,674,000 2,587,000 £0.66 £0.21 £0.65
Hepatitis C 954,622 518,000 138,000 £5.57 £9.01 £49.94
Hepatitis E 2,616,000 £0.00
HIV/AIDS 58,512,843 81,547,000 69,363,000 £0.58 £0.46 £0.59
Inﬂuenza 15,784,216 19,244,000 18,932,694 £0.26 £0.33 £0.42
Leishmaniasis 1,974,465 3,317,000 4,283,000 £1.10 £0.95 £0.77
Malaria 33,976,025 82,685,000 65,493,000 £0.68 £0.34 £0.50
Measles 14,852,775 10,420,000 8,051,000 £0.02 £0.04 £0.09
Meningitis 11,426,376 29,399,000 21,014,000 £0.44 £0.14 £0.43
Norovirus
Pertussis 9,881,887 7,018,000 5,250,000 £0.02 £0.03 £0.08
Pneumonia 56,343,025 68,693,000 67,581,770 £0.03 £0.03 £0.08
Salmonella 13,891,385 17,086,000 13,895,104 £0.29 £0.26 £0.63
Schistosomiasis 1,707,143 3,309,000 3,062,000 £3.00 £1.01 £1.82
Shigellosis 5,733,469 7,052,000 5,735,004 £0.05 £0.04 £0.12
Syphilis 2,846,113 9,578,000 11,324,000 £0.04 £0.01 £0.01
Tetanus 5,283,485 4,663,000 3,654,000 £0.02 £0.09 £0.20
Trypanosomiasis 1,672,728 560,000 390,000 £2.44 £9.06 £26.37
Tuberculosis 34,216,000 49,396,000 49,816,000 £0.29 £0.25 £0.50
Varicella 487,000 £0.61
Overall 301,191,800 428,202,000 379,126,770 £2.41 £3.59 £5.10
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Fig. 3. Investment by mortality observed for selected infections and across three time
points.
187M.G. Head et al. / EBioMedicine 3 (2016) 180–190considering time points 2004, 2010 and 2013, the median investment
by mortality observed was £17.20, but greatest in 2013 (£31.16). HIV
and malaria investments were above the median level at each time
point; tuberculosis was below the median level (Table 3, Fig. 3).
Compared to mortality, little investment was directed towards chol-
era, syphilis and pneumonia. Vaccine-preventable diseases such as
diphtheria, measles and pertussis were mostly ranked as poorly-
invested, though their respective investment by mortality observed
noticeably increased in 2013 as global burdens declined. The ‘invest-
ment per DALY observed’ metric (Table 4, Fig. 4) demonstrated sim-
ilar ﬁndings to the mortality metric, with pneumonia appearing
poorly-invested compared to other particularly high-burden infec-
tions such as malaria, and cholera, syphilis and pertussis also receiv-
ing little funding. Acute hepatitis C, African trypanosomiasis and
chlamydia demonstrated the highest relative investment when
compared to DALYs.
Ranking infections by investment and disease burden in 2013,
Table 5 describes how HIV (9th) and malaria (10th) were mid-
ranking diseases, with tuberculosis (14th) and pneumonia (20th)
ranked lower. Acute hepatitis C, African trypanosomiasis and leishman-
iasis were the top three infections, and pertussis, cholera and syphilis
the bottom three. Diphtheriawas ranked in the lowest threewhen com-
pared against mortality and DALYs, whilst gonorrhoea was ranked in
the lowest three when compared against YLD.Fig. 4. Investment by DALYs observed for selected infections and across three time points.4. Discussion
We identiﬁed 7398 awards for infectious disease research awarded
to UK institutions across the 17 year time period of 1997–2013, with
total funding of £3.7 billion. Relative to measures of investment com-
pared to global mortality, DALYs and YLD, acute hepatitis C, trypanoso-
miasis and leishmaniasis rank highly whilst Shigellosis, pertussis,
cholera and syphilis consistently rank lowest; tuberculosis typically
ranked lower than HIV or malaria, and pneumonia appears to receive
particularly low levels of investment compared to mortality and
DALYs. The overall level of investment and the median investment by
mortality, DALY and YLD observed increased in 2013 compared with
previous time points, owing to both increases in research investment
and decreases in the global burden of infectious disease.
The comparison with global burden of disease and the development
of associated metrics demonstrates the need for consideration of more
than one measure of burden. Pneumonia, a disease with relatively
highmortality, receives low levels of research investmentwhen consid-
ering just mortality or DALYs, but ranks higher when considering life-
long measures of burden such as YLDs. Chlamydia, a disease of low
mortality, ranks highly when comparing investment with mortality
but the YLD ranking is lower. Chronic infections are also difﬁcult to ac-
count for, as demonstrated by the high ranking of acute hepatitis C,
which does not fully take into account the chronic and undiagnosed
burden or the projected future burden.
Several of the infections studied are vaccine-preventable, such as
measles, pertussis and diphtheria, and policymakers need to decide
whether to fund, for example, operational research to identify improve-
ments in the delivery process of vaccine, or to investmore heavily in im-
plementation measures known to be effective. Expanding on this work
to incorporate further measures of burden across different time points
and to take into account proportions of funding for each type of science
would strengthen these models. Replication of the study using data
from other countries and in non-communicable disease area would
also provide a more complete picture of diseases where there have
been adequate or inadequate investment. Further work to decipher
the impact of predominantly UK-focused funders, such as the NIHR,
and the global funding remit of the organisations such as theWellcome
Trust would also be useful.
There are other published analyses that have similar aims in terms of
considering investment and burden. Consideration of NIH funding in
2006 suggested a modest correlation with USA disease burden from
2004, (Gillum et al., 2011) with comparable ﬁndings in analyses from
Australia (Mitchell et al., 2009) and Norway (Kinge et al., 2014), show-
ing variable correlation depending upon the chosen burden metric and
whether that metric considered national or global burden. Thus,
policymakers have a decision to make about the extent to which there
is targeting of investment on health burdens within their own country,
and how much funding targets international priorities. These decisions
will be driven to an extent by the remits of existing funding agencies,
plus also the existing research expertise in the UK. Disease areas such
as the NTDs appear well-funded here, relative to their global disease
burden, and this ismay be in part due to previous and ongoing excellent
performance by individuals and institutions in addressing these areas.
In terms of the location of research investment activity, the UK demon-
strably provides greater relative international investment in nations
where there are colonial ties (Fitchett et al., 2014c). It may be that
other nations also favour countries in which they have historic connec-
tions (and there are good reasons for doing so, such as a common lan-
guage or infrastructure requirements); however, this may also mean
that some countries are neglected in terms of receiving research invest-
ment from which they could greatly beneﬁt.
Funding for infectionswith pandemic potential remains inconsistent
and it is difﬁcult to project accurate future burdens of new and emerg-
ing infectious diseases. The UK inﬂuenza research portfolio is now argu-
ably relatively strong, combined with a Department of Health focus to
Table 5
Rankings of research investment for 25 infectious diseases compared with 2013 YLD, mortality and DALYs.
Disease Research investment (UK pound) by burden observed, 2013
Mean ranking across all burden metrics Mortality Years lived with disability Disability-adjusted life years
Hepatitis C 1.00 1 1 1
Trypanosomiasis 2.00 2 2 2
Leishmaniasis 6.67 8 5 7
Dengue 7.33 5 14 3
Inﬂuenza 8.33 7 4 14
Chlamydia 8.67 3 19 4
Schistosomiasis 9.67 4 20 5
Salmonella 10.00 12 9 9
Malaria 11.00 11 10 12
HIV/AIDS 11.67 14 11 10
Chagas Disease 12.00 13 17 6
Hepatitis B 12.00 16 12 8
Campylobacter 12.33 6 16 15
Tuberculosis 13.67 17 13 11
Tetanus 14.00 18 6 18
Meningitis 14.33 15 15 13
E. coli 15.67 9 21 17
Measles 16.00 20 8 20
Diphtheria 16.33 23 3 23
Pneumonia 16.33 21 7 21
Gonorrhoea 16.67 10 24 16
Shigellosis 20.00 19 22 19
Pertussis 20.67 22 18 22
Cholera 23.67 24 23 24
Syphilis 25.00 25 25 25
188 M.G. Head et al. / EBioMedicine 3 (2016) 180–190identify research gaps and priorities in this area (Infectious Disease
Research Network, 2014). The emergence of the large Ebola outbreak
in West Africa over 2014 and 2015 has highlighted how little research
there has been byUK institutionsprior to 2014 onﬁloviruses; anunpub-
lished analysis using ResIn data demonstrates that the US NIH is the
only funder with a track record of sustained funding in this area. Reac-
tive efforts across 2014 and beyond will greatly increase that total
research investment; however, the examples of Ebola and novel
coronaviruses with pandemic potential (Head et al., 2014a) show that
there is a need for a proactive approach in terms of commissioning,
capacity-strengthening and carrying out research in diseases that have
potential to impact on global health security (though this area of
commissioning faces signiﬁcant challenges). Decisions around resource
allocation for disease eradicationmay reﬂect the interests of speciﬁc do-
nors and high-proﬁle individuals, such as former US President Jimmy
Carter and his efforts towards eradicating dracunculiasis (Guinea
worm) (Hopkins et al., 2014), though most investment here would be
considered implementation rather than research. In 2015, the UK gov-
ernment announced a high-proﬁle implementation and research in-
vestment in collaboration with the Bill & Melinda Gates Foundation to
advance knowledge against infectious diseases, particularly malaria
(HM Treasury D for ID, 2015). Clearly, there are other factors beyond
current and projected disease burdens that should inﬂuence decisions
around research investment priorities, such as the effectiveness of avail-
able interventions, what constitutes the ‘best buy’ for a particular health
service and consideration of health inequity in neglected populations
(Wiseman and Mooney, 1998). There should also be reﬂections on
what research is feasible and the likelihood of advances in knowledge
if investment is targeted in speciﬁc disease or geographical areas. A
checklist for health research priority setting, with the aim of achieving
maximum public health beneﬁt, has been suggested previously
(Viergever et al., 2010), and the data presented here showing the rela-
tive scale of investment compared to disease burden can usefully inform
the commissioning process for research that assesses how to alleviate
the impact of disease on public health.
There have been demonstrable shifts in the proportions of the
type of science allocated to some disease areas, and this will affect
the likely temporal impacts of R&D on public health and patient careand thus the burden of disease. For example, over 80% of gastroenterol-
ogy research was pre-clinical in 1997–2010; across 2011–2013, less
than half was pre-clinical with relatively equal sums of money for the
other four phases of research. This may be the result of the previous
pre-clinical research being translated into tools, products or knowledge
in other areas of the research pipeline, and may have contributed to
the reduction in global burden of disease observed in enteric infections
in 2013. The level of investment by the private sector in new tools
such as vaccines, therapeutics and diagnostics for infectious diseases is
important but uncertain given the low market attractiveness for
these conditions which predominantly affect lower income and middle
income countries, though it is plausible that investment decisions in
the public, philanthropic and private sector are made as a result of
some level of interaction between the sectors. There are examples of
public–private product development partnerships for infections such
as malaria and TB, while that for maternal and child health, where
there is also low market attractiveness, has been lacking (Fisk and
Atun, 2008). Although there has been progress madewith transparency
of reporting in the pharmaceutical and biotechnology industries
(Brown, 2013), commercial sensitivities mean that it is difﬁcult to ob-
tain investment data to analyse in similar detail to the awards included
here.
The low levels of research investment for syphilis and gonorrhoea
remain (Head et al., 2013, 2015b), both in terms of total funding but
also when compared to disease burden. Given the increasing levels of
antibiotic resistance in strains ofNeisseria gonorrhoeae, and the continu-
ing high burden of both these otherwise-treatable infections, they seem
an area worthy of greater focus by UK research institutions and funders.
Sepsis remains hugely problematic inmany healthcare settings, and the
research portfolio needs to be increased to reﬂect this.
The temporal trends in funding for infectious disease research has
been noted as being volatile (Fitchett et al., 2014b), for example the
peak in year 2000 (Fig. 1a) being partly due tomarkedly increased con-
tributions from the Bill & Melinda Gates Foundation in that year (£40.1
million, compared with zero UK research investment in 1999 or 2001).
This will result in ﬂuctuations in levels of funding for several infections;
for example here across 1997–2010 and 2011–2013, investments for
Candida proportionately increased and investments for HPV decreased
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various issues such as funder priorities, numbers of applications re-
ceived by those funders, disbursement of research funds over the
study period, research capacity in each topic area, and potentially the
quality of burden data available.
This study has several limitations, some of which have been de-
scribed previously (Head et al., 2013). An additional limitation is that
our analyses will exclude much infrastructure funding that some
funders invest in quite heavily and this may underestimate total invest-
ment in infectious disease research aswell as the contribution of speciﬁc
funders. As described above, the lack of private sector investment infor-
mation leaves a data gap. Analyses have not taken into account propor-
tions of awards allocated to indirect or estate costs. Any distribution of
funding from the lead centre to collaborating partners is also not docu-
mented. Categorisation is subjective, but checks by at least oneother au-
thor reduce the impact of any observer error. This analysis is also
vulnerable to the effects of any changes in methodology of the GBD
study, and there will also be uncertainty in the disease estimates calcu-
lated in the GBD analyses.
Public and philanthropic research funding for infectious diseases has
increased in the time period 2011–2013 as compared with previous
years, with greater mean and median award amounts, indicating a
shift towards funding award types such as consortia or programme
grants. Measuring these investments against the global burden of dis-
ease highlight areas such as inﬂuenza and trypanosomiasis where the
UK has relatively strong investment and probable research strengths,
but areas such as sepsis, pneumonia, syphilis and gonorrhoea remain
areas of relative underinvestment, and should be considered by funding
organisations and policymakers. Co-ordinated efforts across the global
health community must consider research investment in emerging in-
fectious diseases and pathogens of pandemic potential. By demonstrat-
ing potential inequities in allocation of investment and disease burden,
analyses by the ResIn study can contribute to priority setting by funders
and inform strategy of policymakers, government departments and re-
search institutions.
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